Korea’s first homegrown GLP-1: Can Hanmi’s Eppe undercut Mounjaro and Wegovy?

Hanmi Pharmaceutical’s Eppe is poised to challenge Wegovy and Mounjaro in Korea’s fast-growing obesity drug market, with price emerging as a potentially decisive advantage. The homegrown glucagon-like peptide-1, or GLP-1, drug is expected to launch before year-end, pending approval from the Ministry of Food and Drug…

Opens the original publisher in a new tab. Full articles belong to their publishers; a subscription may be required.